The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya

Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC...

Full description

Saved in:
Bibliographic Details
Main Authors: Francis Mugeni Wanyama (Author), Rudolf Tauber (Author), Alfred Mokomba (Author), Catherine Nyongesa (Author), Véronique Blanchard (Author)
Format: Book
Published: MDPI AG, 2022-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_eb19dba4f03947d58617fa274a48d407
042 |a dc 
100 1 0 |a Francis Mugeni Wanyama  |e author 
700 1 0 |a Rudolf Tauber  |e author 
700 1 0 |a Alfred Mokomba  |e author 
700 1 0 |a Catherine Nyongesa  |e author 
700 1 0 |a Véronique Blanchard  |e author 
245 0 0 |a The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya 
260 |b MDPI AG,   |c 2022-06-01T00:00:00Z. 
500 |a 10.3390/idr14030047 
500 |a 2036-7449 
520 |a Ovarian cancer (OC) is a gynecological malignancy characterized by high morbidity and mortalities due to late-stage diagnosis because accurate early diagnostic biomarkers are lacking. Testing of Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections in OC patients is pertinent in light of the emerging evidence of their contribution to poor prognosis. We, for the first time, investigated the prevalence of HBV, HCV, and HIV infections in a Kenyan cohort of OC to inform optimal management. We recruited a cohort of women above 18 years of age, comprising 86 OC patients and 50 healthy controls. Participants' blood samples were serologically screened for HBV, HCV, and HIV. We found seroprevalence rates of 29.1%, 26.7%, and 1.2% for HBV, HIV, and HCV, respectively, in OC patients. The healthy control group had HBV and HIV seroprevalence rates of 3.9% for each with no positive HCV case. HBV/HIV coinfection was noted only in the OC group with a positivity rate of 17.4%. In summary, we found higher HBV and HIV seroprevalence in Kenyan OC patients compared to the healthy control group, whereas HCV prevalence was reflective of the general population. Hence, we recommend screening for HBV and HIV among OC patients destined for anticancer treatment. 
546 |a EN 
690 |a ovarian cancer 
690 |a hepatitis B virus 
690 |a human immunodeficiency virus 
690 |a hepatitis C virus 
690 |a seroprevalence 
690 |a chemotherapy 
690 |a Other systems of medicine 
690 |a RZ201-999 
655 7 |a article  |2 local 
786 0 |n Infectious Disease Reports, Vol 14, Iss 3, Pp 433-445 (2022) 
787 0 |n https://www.mdpi.com/2036-7449/14/3/47 
787 0 |n https://doaj.org/toc/2036-7449 
856 4 1 |u https://doaj.org/article/eb19dba4f03947d58617fa274a48d407  |z Connect to this object online.